Research Article

Determinants of Deescalation Failure in Critically Ill Patients with Sepsis: A Prospective Cohort Study

Nawal Salahuddin,1 Lama Amer,2 Mini Joseph,3 Alya El Hazmi,4 Hassan Hawa,4 and Khalid Maghrabi1

1King Faisal Specialist Hospital & Research Center, Riyadh 11211, Saudi Arabia
2Department of Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia
3Department of Nursing, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia
4Adult Critical Care Medicine, King Faisal Specialist Hospital & Research Center, Riyadh 11211, Saudi Arabia

Correspondence should be addressed to Nawal Salahuddin; salahuddin.nawal@gmail.com

Received 27 March 2016; Revised 11 June 2016; Accepted 15 June 2016

Copyright © 2016 Nawal Salahuddin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Deescalation refers to either discontinuation or a step-down of antimicrobials. Despite strong recommendations in the Surviving Sepsis Guidelines (2012) to deescalate, actual practices can vary. Our objective was to identify variables that are associated with deescalation failure. Methods. In this prospective study of patients with sepsis/septic shock, patients were categorized into 4 groups based on antibiotic administration: no change in antimicrobials, deescalation, escalation (where antibiotics were changed to those with a broader spectrum of antimicrobial coverage), or mixed changes (where both escalation to a broader spectrum of coverage and discontinuation of antibiotics were carried out). Results. 395 patients were studied; mean APACHE II score was 24 ± 7.8. Antimicrobial deescalation occurred in 189 (48%) patients; no changes were made in 156 (39%) patients. On multivariate regression analysis, failure to deescalate was significantly predicted by hematologic malignancy OR 3.3 (95% CI 1.4–7.4) p < 0.004, fungal sepsis OR 2.7 (95% CI 1.2–5.8) p = 0.011, multidrug resistance OR 2.9 (95% CI 1.4–6.0) p = 0.003, baseline serum procalcitonin OR 1.01 (95% CI 1.003–1.016) p = 0.002, and SAPS II scores OR 1.01 (95% CI 1.004–1.02) p = 0.006. Conclusions. Current deescalation practices reflect physician reluctance when dealing with complicated, sicker patients or with drug-resistance or fungal sepsis. Integrating an antibiotic stewardship program may increase physician confidence and provide support towards increasing deescalation rates.

2. Methods

This study is reported following the STROBE statement checklist for observational studies [1].

2.1. Ethics, Consent, and Permissions. The institutional Office of Research Affairs (ORA) and ORA Research Ethics Committee approved the study methods (RAC number 2131108). The Research Ethics Committee waived patient consent based on the study design. The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.
2.3. Operational Definitions. Antibiotic therapy was considered appropriate based on in vitro sensitivity on culture. On day 7 after ICU admission, we categorized patients into four groups based on antibiotic administration: no change in antibiotics, deescalation (defined as stopping or changing to a narrower spectrum antibiotic), escalation (where antibiotics were changed to those with a broader spectrum of antimicrobial coverage), or mixed changes (where both escalation to a broader spectrum of coverage and discontinuation of antibiotics were carried out).

2.4. Statistical Analysis. Continuous data was tested for normality; measures of central tendency were reported as means ± standard deviations (SD) and compared using Student’s t-test for normally distributed variables and reported as medians (interquartile range, IQR) and compared using the Mann-Whitney U test for skewed data. Categorical variables were compared using the \( \chi^2 \) test or the Fisher Exact test for \( n < 5 \). Logistic regression analysis was performed to determine the predictive ability of variables for antibiotic deescalation. Univariate and multivariate techniques were used, and, for multivariate regression, a backward mode with a threshold 0.10 was used for elimination. Multivariate associations were reported as odds ratios, Exp(\( \beta \)) with 95% confidence intervals. A two-sided \( p \) value of < 0.05 was considered as statistically significant. All analyses were carried out using IBM SPSS version 22.0.

3. Results

Three hundred and ninety-five patients were included in the study; 194 (49%) were female, mean age of 52.4 ± 12 years; mean APACHE II and SAPS II scores were 24 ± 7.8 and 45 ± 19.7. Three hundred and thirty-three (84.3%) patients were admitted from within the hospital, 58 (14.7%) were admitted from the emergency department, and 4 (1%) came as inter-hospital transfers via MEDEVAC. Two hundred and forty-eight (63%) patients were admitted after working hours 248 (63%) of whom 214 (86%) came from the hospitals, 30 (12%) from the emergency department, and 4 (2%) as transfers. Only 195 (49.3%) of the total 395 patients had positive cultures. Nosocomial acquisition of sepsis was confirmed in 105 (75%) of 139 culture-positive patients

### Table 1: Characteristics of patients.

| Patient characteristics                        | \( n = 395 \) |
|-----------------------------------------------|--------------|
| APACHE II score                              | 24 ± 78      |
| Serum procalcitonin                          | 3.9 (IQR 25% 1.1, 75% 18.4) |
| Admission during working hours               | 147 (37%)    |
| Admission after working hours                | 248 (63%)    |
| Vasopressors at 72 hours                     | 236 (60%)    |
| Comorbid illnesses                           |              |
| Malignancy                                    | 86 (22%)     |
| Metastatic cancer                             | 26 (7%)      |
| Hematologic malignancy                        | 35 (9%)      |
| Acute respiratory failure                     | 67 (17%)     |
| Chronic renal failure                         | 64 (16%)     |
| Dialysis dependent                            | 42 (11%)     |
| Cirrhosis                                     | 62 (16%)     |
| Chronic diseases*                             | 235 (59%)    |
| No microbial growth on admission cultures     | 200 (51%)    |
| Source of sepsis                              |              |
| BSI                                           | 83 (42%)     |
| Respiratory                                   | 72 (37%)     |
| Urinary tract                                 | 27 (14%)     |
| Peritonitis                                    | 11 (5%)      |
| Surgical site                                 | 10 (5%)      |
| Multidrug resistant organisms                 | 41 (21%)     |
| Fungal organisms                              | 36 (18%)     |
| Initial antimicrobial therapy appropriate      | 112 (57%)    |
| ICU length of stay (days)                     | 6 (IQR 39)   |
| ICU mortality                                 | 74 (48.7%)   |
| 28-day mortality                              | 114 (28.9%)  |

*p refers to chronic medical illnesses, that is, type 2 diabetes mellitus, coronary artery disease, and hypertension.

### Table 2: Frequencies of all microbial isolates.

| Organisms isolated       | Number* |
|--------------------------|---------|
| Enterobacteriaceae*      | 57 (29.2%) |
| Pseudomonas aeruginosa   | 53 (27.1%) |
| GPC*                     | 21 (10.7%) |
| Fungal                   |          |
| Candida albicans         | 11 (5.6%)  |
| Candida non-albicans     | 13 (6.6%)  |
| Aspergillus              | 1        |
| Stenotrophomonas maltophilia | 8 (4%)    |
| MRSA                     | 7 (3.5%)  |
| Acinetobacter baumannii  | 7 (3.5%)  |
| VRE                      | 5 (2.5%)  |
| Viruses*                 | 3 (1.5%)  |
| Miscellaneous*††         | 9 (16%)   |

* Out of 195 positive cultures; † includes Escherichia coli, Klebsiella, Enterobacter, Citrobacter koseri, and Proteus mirabilis; †† includes Streptococcus sp. and methicillin-sensitive Staphylococcus aureus; ††† includes MERS-corona, parainfluenza, and influenza; †‡ includes Alcaligenes xylosoxidans, Vibrio cholerae, Mycobacterium tuberculosis, and Nocardia.
Table 3: Differences in patient characteristics by final antibiotic grouping.

|                                | Deescalation | No change | Escalation | Mixed changes | p value |
|--------------------------------|--------------|-----------|------------|---------------|---------|
| SAPS II                         | 48 ± 19.5    | 41 ± 19   | 47 ± 18.5  | 44 ± 23.7     | 0.007   |
| Admission procalcitonin         | 2.3 (IQR 0.7–7.4) | 79        | 4.6        | 11.1          | 0.007   |
| No growth                       | 86 (45.5%)   | 102 (65.3%) | 12 (28.5%) | 0             | <0.001  |
| Single site of sepsis           | 60 (31.7%)   | 35 (22.4%) | 22 (52.3%) | 3 (37.5%)     | 0.002   |
| MDR organism                    | 12 (6.3%)    | 22 (14.1%) | 5 (11.9%)  | 2 (25%)       | 0.05    |
| Fungal sepsis                   | 11 (5.8%)    | 15 (9.6%)  | 8 (19%)    | 2 (25%)       | 0.019   |
| ICU length of stay              | 6.5 (IQR 4.2–44) | 5.5       | 5          | 7.5           | 0.003   |
| ICU mortality                   | 28 (14.8%)   | 38 (24.4%) | 6 (14.3%)  | 2 (25%)       | 0.11    |

Table 4: Multivariate regression analysis to indicate variables associated with no deescalation of antimicrobials.

|                                | Wald statistic | Exp(B) | 95% CI for Exp(B) | p value |
|--------------------------------|----------------|--------|-------------------|---------|
| Hematologic malignancy         | 8.31           | 3.30   | 1.46              | 7.44    | 0.004   |
| Admission procalcitonin        | 9.73           | 1.01   | 1.004             | 1.016   | 0.002   |
| Fungal sepsis                  | 6.50           | 2.70   | 1.25              | 5.80    | 0.011   |
| MDR organisms isolated         | 8.58           | 2.94   | 1.43              | 6.07    | 0.003   |
| SAPS II score                  | 7.59           | 1.01   | 1.004             | 1.026   | 0.006   |

Admitted “after-hours” and in 50 [89%] inpatients of 56 culture-positive patients admitted during “regular” hours. Patients with hematologic malignancy comprised 106 (26.8%) of the admissions; detailed patient characteristics are shown in Table 1.

Empiric antibiotics were a combination of vancomycin, 292 patients (74%), and carbapenem, 277 patients (70%), with colistin, 70 patients (18%), aminoglycosides, 37 (9%), and quinolones, 64 (16%), used in addition. Empiric caspofungin was added in 47 (12%) patients. Most frequent empirical antibiotic regimen used was vancomycin + carbapenem, 193 (49%), followed by vancomycin + extended-spectrum penicillin/β-lactamase inhibitor, 131 (33%), and vancomycin and aminoglycosides or quinolones, 71 (18%). Cultures were positive in 195 (49.4%) patients and 200 (50.6%) remained culture negative.

Please refer to Table 2 for frequencies of all isolates.

Empiric therapy was appropriate in 57% cases. The median ICU length of stay was 6 days (IQR 4–43) with a 28-day survival rate of 71% (281 patients).

Antimicrobial deescalation was carried out in 189 (48%) patients; in 156 (39%) patients no changes in the antimicrobial regimen were made; 42 (11%) patients had their antimicrobial coverage escalated and in 8 (2%) patients mixed changes were made.

Please refer to Table 3 for differences in patient characteristics by final antibiotic grouping.

In a comparison of patients that were deescalated compared to patients “not deescalated” (combination of groups with escalation, no changes, or both escalation and deescalation, i.e., mixed changes), rates of malignancy, multidrug resistant (MDR) organisms, fungal sepsis, chronic organ failure (renal, liver), baseline APACHE II, SAPS II, and serum procalcitonin were significantly different. Deescalation rates were not significantly different between patients with positive cultures and those with negative cultures or single versus multiple positive culture sites or when the patient continued to be vasopressor-dependent. Deescalation was associated with a significantly lower ICU mortality compared to patients not deescalated, 27 out of 188 patients (14.3%) versus 47 out of 207 patients (22.7%).

3.1. Univariate Outcome Data. On univariate regression analysis failure to deescalate was significantly predicted by APACHE II and SAPS II scores, OR 1.02 (95% CI 1.002–1.05, p = 0.037) and OR 1.01 (95% CI 1.005–1.02, p = 0.004), baseline serum procalcitonin OR 1.01 (95% CI 1.003–1.016, p = 0.003), hematologic malignancy OR 2.85 (95% CI 1.3–6.2, p = 0.009), isolation of MDR organisms OR 2.39 (95% CI 1.18–4.8, p = 0.015), and fungal sepsis OR 2.21 (95% CI 1.05–4.62, p = 0.035).

3.2. Multivariate Analysis. After adjusting for covariates, serum procalcitonin, OR 1.01 (95% CI 1.004–1.016) p = 0.002, SAPS II scores OR 1.01 (95% CI 1.004–1.02), p = 0.006, hematologic malignancy OR 3.3 (95% CI 1.4–7.4) p < 0.004, fungal sepsis OR 2.7 (95% CI 1.2–5.8) p = 0.011, and MDR isolates OR 2.9 (95% CI 1.4–6.0) p = 0.003 remained significant predictors for no deescalation.

Please refer to Table 4 showing multivariate regression analysis to indicate variables associated with no deescalation of antimicrobials.
Table 5: Summary of studies on antibiotic deescalation.

| Study type                  | Setting                              | Patients | Deescalation rate | Association with outcomes                                                                 | Factors associated with no deescalation |
|-----------------------------|--------------------------------------|----------|-------------------|------------------------------------------------------------------------------------------|----------------------------------------|
| Rello et al., 2004 [2]      | Prospective, observational            | 115      | 31.4%             | Not reported                                                                             | Nonfermenting Gram-negative bacillus   |
|                             | Medical-surgical ICU with VAP         |          |                   |                                           | (2.7% versus 49.3%), late-onset pneumonia (12.5% versus 40.7%), \( p < 0.05 \) |
| Eachempati et al., 2009 [3] | Observational                        | 138      | 55%               | No difference in recurrent pneumonia rate or mortality, 34% versus 42%                   | Not reported                            |
|                             | Surgical ICU with VAP                 |          |                   |                                           |                                        |
| De Waele et al., 2010 [4]   | Retrospective                         | 113      | 42%               | No difference in mortality rate (7% versus 21%, \( p = 0.12 \))                         | Negative cultures, colonization with   |
|                             | Surgical ICU                          |          |                   |                                           | multiresistant Gram-negative organisms |
| Hibbard et al., 2010 [5]    | Retrospective                         | 811      | 78%-59%           | No change in resistance rates                                                          | Not reported                            |
|                             | Surgical ICU, VAP                     |          |                   |                                           |                                        |
| Morel et al., 2010 [6]      | Retrospective                         | 116      | 45%               | Recurrent infection (19% versus 5%, \( p = 0.01 \))                                     | Inadequate empiric antibiotic and initial |
|                             | Mixed ICU                             |          |                   |                                           | therapy not containing aminoglycoside    |
| Gonzalez et al., 2013 [7]   | Retrospective                         | 229      | 51%               | No differences in mortality, length of stay, antibiotic duration, mechanical ventilation,|
|                             | Medical ICU                           |          |                   | ICU-acquired infection, or drug-resistant bacteria                                         |                                        |
| Duchène et al., 2013 [8]    | Retrospective                         | 80       | 46%               | Not reported                                                                             | Shock, renal abscess, obstructive       |
|                             | Urosepsis                             |          |                   |                                           | uropathy, bacterial resistance          |
| Garnacho-Montero et al., 2014 [9] | Prospective, observational          | 712      | 34.9%             | Deescalation protective for mortality (OR 0.54; 95% CI 0.33-0.89)                      | Not reported                            |
|                             | Medical                               |          |                   |                                           |                                        |
| Carugati et al., 2015 [10]  | Secondary analysis of CAP database    | 261      | 63.2%             | No association with mortality                                                          | More severe presentation               |
|                             | Medical with CAP                      |          |                   |                                           |                                        |
| Lee et al., 2015 [11]       | Retrospective                         | 189      | 45.5%             | Deescalation strategy was protective for mortality (OR 0.37, \( p = 0.04 \))            | Not reported                            |
|                             | Community-onset monomicrobial Enterobacteriaceae (CoME) bacteremia |          |                   |                                           |                                        |
| Madaras-Kelly et al., 2016 [12] | Retrospective                         | 9319     | 28.3%             | Not reported                                                                             | Deescalation associated with initial   |
|                             | HCAP in VA system                     |          |                   |                                           | broad-spectrum therapy (OR 1.5, 95% CI 1.4–1.5), collection of respiratory tract cultures (OR 1.1, 95% CI 1.0–1.2), care in higher complexity facilities (OR 1.3, 95% CI 1.1–1.6) |
Table 5: Continued.

| Study type          | Setting                | Patients | Deescalation rate | Association with outcomes                                                                 | Factors associated with no deescalation |
|---------------------|------------------------|----------|-------------------|------------------------------------------------------------------------------------------|----------------------------------------|
| Falguera et al., 2010 [13] RCT | Community-acquired pneumonia | 177, deescala- tion by urinary antigen results | — | Higher cost ($p = 0.28$), reduced adverse events (9% versus 18%, $p = 0.12$), lower exposure to broad-spectrum antimicrobials (154.4 versus 183.3 daily doses per 100 patient days) |
| Kim et al., 2012 [14] RCT | Medical ICU, hospital-acquired pneumonia | 109 | — | No differences in ICU stay or mortality rates, higher risk of MRSA with deescalation; HR 3.84; 95% CI 1.06–13.91 |
| Leone et al., 2014 [15] Multicenter, RCT | Severe sepsis | 60 | — | Deescalation resulted in prolonged duration of ICU stay; mean difference 3.4 (95% CI −1.7–8.5); no effect on mortality | Not reported |

ICU: intensive care unit; VAP: ventilator-associated pneumonia; CAP: community-acquired pneumonia; HCAP: healthcare associated pneumonia; HR: hazard ratio; OR: odds ratio.

4. Discussion

In this prospective study of critically ill, septic patients antimicrobial deescalation was carried out in less than half of all patients, with higher baseline procalcitonin levels, greater organ dysfunction scores, comorbid hematologic malignancy, isolation of drug-resistant bacteria, and fungal organisms identified as independent predictors of failure to deescalate.

The morbidity and costs of continued broad-spectrum antimicrobials and the safety of deescalation are now well established in the medical literature. A deescalation strategy has not been shown to be harmful in patients with varied immunestatuses or systemic or limited infections or in fungal septicemia [7, 11, 12, 16–25] and in fact may even exert a protective effect as reported by Lee et al. [11] and Garnacho-Montero et al. [9].

Please see Table 5 for a summary of recent studies on antibiotic deescalation.

Despite reports of benefit, deescalation remains variably practiced with rates from 10 to 60% [26]. Please refer to Table 5. In our cohort of multidisciplinary critically ill patients with sepsis and shock, antimicrobial deescalation was carried out in 48% patients, which is comparable to that reported by other investigators.

The real question then is when are physicians less likely to deescalate? Recent studies have shown that antibiotic deescalation becomes less likely with severe, complicated infections and drug-resistance and when initial antibiotic therapy is inadequate. Please refer to Table 5. In our study, deescalation failure was predicted by the isolation of drug-resistant bacteria and fungal organisms, greater severity of illness as demonstrated by higher initial organ dysfunction scores, underlying hematologic malignancy, and a procalcitonin level that may suggest a greater bacterial load.

What then appears to be a common theme here is that physicians are uncomfortable deescalating antimicrobials when faced with sicker patients with a higher possibility of complications. Antimicrobial stewardship is a strategy that employs availability of either an infectious disease specialist and/or a clinical pharmacist to assist in decision-making at the bedside. Stewardship programs have been shown to successfully reduce resistance patterns, reduce antibiotic usage, and reduce costs without increasing adverse outcomes [27–34]. Our study confirms the results of others that there is a real need for and potential benefits of implementing antimicrobial stewardship programs across all areas where broad-spectrum antimicrobials are utilized. Whether they are specialty driven or pharmacy-led should be tailored to the resources available to individual centers.

This study’s strengths are its large numbers of patients and the generalizability of our results to other ICUs. We have a varied case-mix from our surgical and medical ICUs with causative organisms that are similar to those isolated from most ICUs. The limitation of our results is that this is a single-center study.

Assisting the stewardship model is a recent publication from de Jong and colleagues [35] where, in a controlled trial in 15 Netherland hospitals, ICU admissions were randomized to usual care versus antibiotic deescalation once procalcitonin levels decreased by 80% or more of its peak value or to 0.5 μg/L or lower. Mortality was significantly lower in the procalcitonin-guided group, between-group absolute difference 5.4% (95% CI 1.2–9.5, $p = 0.0122$). Therefore, procalcitonin absolute levels and patterns may assist bedside decision-making incorporated into an antibiotic stewardship program.

5. Conclusions

Current deescalation practices reflect physician reluctance when dealing with complicated, sicker patients or with drug-resistance or fungal sepsis. Integrating an antibiotic
stewardship program may increase physician confidence and provide support towards increasing deescalation rates.

Competing Interests

There are no competing interests to declare.

Acknowledgments

The authors are indebted to Ahmed Kamal, MD, Assistant Consultant Adult Critical Care Medicine, KFSHRC, for his assistance in data collection.

References

[1] E. von Elm, M. Egger, D. G. Altman, S. J. Pocock, P. C. Gøtzsche, and J. P. Vandenbroucke, “Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies,” British Medical Journal, vol. 335, no. 7624, pp. 806–808, 2007.

[2] J. Bello, L. Vidaur, A. Sandiumenge et al., “De-escalation therapy in ventilator-associated pneumonia,” Critical Care Medicine, vol. 32, no. 11, pp. 2183–2190, 2004.

[3] S. R. Echampati, L. J. Hydo, J. Shou, and P. S. Barie, “Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients?” The Journal of Trauma, vol. 66, no. 5, pp. 1343–1348, 2009.

[4] J. J. De Waele, M. Ravys, P. Depuydt, S. I. Blot, J. Decruyenaere, and D. Vogelaers, “De-escalation after empirical meropenem treatment in the intensive care unit: fiction or reality?” Journal of Critical Care, vol. 25, no. 4, pp. 641–646, 2010.

[5] M. L. Hibbard, T. R. Kopelman, P. J. O’Neill et al., “Empiric, broad-spectrum antibiotic therapy with an aggressive de-escalation strategy does not induce gram-negative pathogen resistance in ventilator-associated pneumonia,” Surgical Infections, vol. 11, no. 5, pp. 427–432, 2010.

[6] J. Morel, J. Casoetto, R. Jospé et al., “De-escalation as part of a global strategy of empiric antibiotic therapy management. A retrospective study in a medico-surgical intensive care unit,” Critical Care, vol. 14, no. 6, article R225, 2010.

[7] L. Gonzalez, A. Cravoisy, D. Barraud et al., “Factors influencing the implementation of antibiotic de-escalation and impact of this strategy in critically ill patients,” Critical Care, vol. 17, no. 4, article R140, 2013.

[8] E. Duchêne, E. Montassier, D. Boutoille, J. Caillon, G. Potel, and E. Batard, “Why is antimicrobial de-escalation under-prescribed for urinary tract infections?” Infection, vol. 41, no. 1, pp. 211–214, 2013.

[9] J. Garnacho-Montero, A. Gutiérrez-Pizarroa, A. Escoresca-Ortega et al., “De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock,” Intensive Care Medicine, vol. 40, no. 1, pp. 32–40, 2014.

[10] M. Carugati, F. Franzetti, T. Wiemken et al., “De-escalation therapy among bacteriaemic patients with community-acquired pneumonia,” Clinical Microbiology and Infection, vol. 21, no. 10, pp. 936.e1–936.e18, 2015.

[11] C.-C. Lee, N.-Y. Lee, P.-L. Chen et al., “Impact of antimicrobial strategies on clinical outcomes of adults with septic shock and community-onset Enterobacteriaceae bacteremia: de-escalation is beneficial,” Diagnostic Microbiology and Infectious Disease, vol. 82, no. 2, pp. 158–164, 2013.

[12] K. Madaras-Kelly, M. Jones, R. Remington et al., “Antimicrobial de-escalation of treatment for healthcare-associated pneumonia within the Veterans Healthcare Administration,” The Journal of Antimicrobial Chemotherapy, vol. 71, no. 2, pp. 539–546, 2016.

[13] M. Falguera, A. Ruiz-González, J. A. Schoenenberger et al., “Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community-acquired pneumonia,” Thorax, vol. 65, no. 2, pp. 101–106, 2010.

[14] J. W. Kim, J. Chung, S.-H. Choi et al., “Early use of imipenem/ cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial,” Critical Care, vol. 16, no. 1, article R28, 2012.

[15] M. Leone, C. Bechis, K. Baumstarck et al., “De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial,” Intensive Care Medicine, vol. 40, no. 10, pp. 1399–1408, 2014.

[16] M. K. Joung, J.-A. Lee, S.-Y. Moon et al., “Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia,” Critical Care, vol. 15, no. 2, article R79, 2011.

[17] N. Shime, S. Satake, and N. Fujita, “De-escalation of antimicrobials in the treatment of bacteremia due to antibiotic-sensitive pathogens in immunocompetent patients,” Infection, vol. 39, no. 4, pp. 319–325, 2011.

[18] K. S. Kaye, “Antimicrobial de-escalation strategies in hospitalized patients with pneumonia, intra-abdominal infections, and bacteremia,” Journal of Hospital Medicine, vol. 7, supplement 1, pp. S13–S21, 2012.

[19] K. V. I. Rolston, S. N. Mahajan, and R. F. Chemaly, “Antimicrobial de-escalation in cancer patients,” Infection, vol. 40, no. 2, pp. 223–224, 2012.

[20] A. Apisarnthanarak, N. Bhooanusas, A. Yaprasert, and L. M. Mundy, “Carbapenem de-escalation therapy in a resource-limited setting,” Infection Control and Hospital Epidemiology, vol. 34, no. 12, pp. 1310–1313, 2013.

[21] M. J. Mosier and H. Ton-That, “Making the case for de-escalation therapy in ventilator-associated pneumonia once again,” Critical Care Medicine, vol. 41, no. 7, pp. 1810–1811, 2013.

[22] R. G. Masterton, M. Casamayor, P. Musingarimi et al., “De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections,” Journal of Medical Economics, vol. 16, no. 11, pp. 1344–1356, 2013.

[23] S. Bailly, O. Leroy, P. Montravers et al., “Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AMAR Cand2 study data,” Intensive Care Medicine, vol. 41, no. 11, pp. 1931–1940, 2015.

[24] D. Mokart, G. Slehofer, J. Lambert et al., “De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study,” Intensive Care Medicine, vol. 40, no. 1, pp. 41–49, 2014.

[25] F. A. Khasawneh, A. Karim, T. Mahmood et al., “Antibiotic de-escalation in bacteremic urinary tract infections: potential opportunities and effect on outcome,” Infection, vol. 42, no. 5, pp. 829–834, 2014.
[26] J. Garnacho-Montero, A. Escoresca-Ortega, and E. Fernández-Delgado, "Antibiotic de-escalation in the ICU: how is it best done?" Current Opinion in Infectious Diseases, vol. 28, no. 2, pp. 193–198, 2015.

[27] S. Cheon, M. J. Kim, S. J. Yun, J. Y. Moon, and Y. S. Kim, "Controlling endemic multidrug-resistant Acinetobacter baumannii in intensive care units using antimicrobial stewardship and infection control," The Korean Journal of Internal Medicine, vol. 31, no. 2, pp. 367–374, 2016.

[28] L. R. Taggart, E. Leung, M. P. Muller, L. M. Matukas, and N. Daneman, "Differential outcome of an antimicrobial stewardship audit and feedback program in two intensive care units: a controlled interrupted time series study," BMC Infectious Diseases, vol. 15, no. 1, article 480, 2015.

[29] A. Hohn, B. Heising, S. Hertel, G. Baumgarten, M. Hochreiter, and S. Schroeder, "Antibiotic consumption after implementation of a procalcitonin-guided antimicrobial stewardship programme in surgical patients admitted to an intensive care unit: a retrospective before-and-after analysis," Infection, vol. 43, no. 4, pp. 405–412, 2015.

[30] D. Hou, Q. Wang, C. Jiang, C. Tian, H. Li, and B. Ji, "Evaluation of the short-term effects of antimicrobial stewardship in the intensive care unit at a tertiary hospital in China," PLoS ONE, vol. 9, no. 7, article e101447, 2014.

[31] M. O. Cotta, J. A. Roberts, A. Tabah, J. Lipman, D. Vogelaers, and S. Blot, "Antimicrobial stewardship of β-lactams in intensive care units," Expert Review of Anti-Infective Therapy, vol. 12, no. 5, pp. 581–595, 2014.

[32] M. R. Amer, N. S. Akhras, W. A. Mahmood, and A. S. Al-Jazairi, "Antimicrobial stewardship program implementation in a medical intensive care unit at a tertiary care hospital in Saudi Arabia," Annals of Saudi Medicine, vol. 33, no. 6, pp. 547–554, 2013.

[33] Y. Ramsamy, D. J. J. Muckart, and K. S. S. Han, "Microbiological surveillance and antimicrobial stewardship minimise the need for ultrabroad-spectrum combination therapy for treatment of nosocomial infections in a trauma intensive care unit: an audit of an evidence-based empiric antimicrobial policy," South African Medical Journal, vol. 103, no. 6, pp. 371–376, 2013.

[34] D. Slain, A. R. Sarwari, K. O. Petros et al., "Impact of a multimodal antimicrobial stewardship program on Pseudomonas aeruginosa susceptibility and antimicrobial use in the intensive care unit setting," Critical Care Research and Practice, vol. 2011, Article ID 416426, 5 pages, 2011.

[35] E. de Jong, J. A. van Oers, A. Beishuizen et al., "Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial," The Lancet Infectious Diseases, vol. 16, no. 7, pp. 819–827, 2016.